Drug loaded contrast agents: combining diagnosis and therapy
US-9220709-B2 · Dec 29, 2015 · US
US10758492B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10758492-B2 |
| Application number | US-201515511847-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 15, 2015 |
| Priority date | Sep 16, 2014 |
| Publication date | Sep 1, 2020 |
| Grant date | Sep 1, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to polymeric structures, in the form of flat membrane-like surfaces or micro- nanostruc-tures such as capsules, characterized in that it comprises a substantially two-dimensional layer of covalently-bonded monomers of R-substituted metal or metalloid oxides. Said polymeric structures in most embodiments have a crystal architecture with a hexagonal lattice, but the nature of the covalent bonds present therein impart a bending flexibility that make the polymeric structures behave as a “soft” crystal. Methods of producing such structures, composition comprising thereof and method of using thereof are also included within the present disclosure.
Opening claim text (preview).
The invention claimed is: 1. A polymeric structure comprising a substantially two-dimensional layer of covalently-bonded monomers of the formula: wherein X is Si, wherein X comprises a hydrophobic moiety comprising at least one carbon atom, wherein the hydrophobic moiety is configured to lie substantially perpendicularly compared to an Euclidean plane the X atoms lie on, wherein the polymeric structure includes a substantially two-dimensional layer with a crystalline structure, wherein the crystalline structure has a hexagonal lattice in which each of the hexagon vertices includes one X atom, and each of the hexagon edges comprises covalently bonded X-O-X atoms, and wherein each of the hexagon lattices share a common edge having the covalently bonded X-O-X atom with a neighboring hexagon such that a flexible honeycomb structure of tessellated hexagons as the substantially two-dimensional layer is provided. 2. The polymeric structure of claim 1 , wherein the X- 0 -X bond angle has a bending flexibility comprised between 120° and 180° with respect to the plane the X atoms lie on. 3. The polymeric structure of claim 1 , wherein R further includes an active agent or is functionalized with an active agent. 4. A composition comprising the polymeric structure of claim 1 . 5. A pharmaceutical composition comprising the polymeric structure of claim 1 . 6. The polymeric structure of claim 1 for use in therapy, prophylaxis or diagnosis of diseases. 7. The polymeric structure of claim 1 for use as ion-selective transport membrane. 8. The polymeric structure of claim 1 for use as molecular size-selective transport membrane. 9. The polymeric structure of claim 1 for use as a coating. 10. The polymeric structure of claim 1 for use in encapsulation of chemical compounds or active agents. 11. The pharmaceutical composition of claim 5 for use in therapy, prophylaxis or diagnosis of diseases. 12. The polymeric structure of claim 2 , wherein the X-O-X bond angle has an equilibrium at 142°. 13. The polymeric structure of claim 1 , wherein the hexagonal lattice includes 6 X atoms at the six vertices of each hexagon. 14. The polymeric structure of claim 1 , wherein the hydrophobic moiety incudes a fluorocarbon and/or a hydrocarbon. 15. The polymeric structure of claim 1 , wherein the hydrophobic moiety includes a aliphatic moiety. 16. The polymeric structure of claim 3 , wherein the active agent includes a hydrophilic agent.
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Processes · CPC title
Inorganic compounds · CPC title
Inorganic compounds · CPC title
Cross-Sectional Technologies · mapped topic
Related publications grouped by family.
Answers are generated from the same data shown on this page.